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A genome-wide screen for genetic alterations in radiation-
induced thymic lymphomas generated from p53þ/  and
p53 /  mice showed frequent loss of heterozygosity
(LOH) on chromosome 6. Fine mapping of these LOH
regions revealed three non-overlapping regions, one of
which was reﬁned to a 0.2Mb interval that contained
only the gene encoding homeobox-interacting protein
kinase 2 (Hipk2). More than 30% of radiation-induced
tumors from both p53þ/  and p53 /  mice showed
heterozygous loss of one Hipk2 allele. Mice carrying a
single inactive allele of Hipk2 in the germline were
susceptible to induction of tumors by c-radiation, but most
tumors retained and expressed the wild-type allele,
suggesting that Hipk2 is a haploinsufﬁcient tumor suppres-
sor gene for mouse lymphoma development. Heterozygous
loss of both Hipk2 and p53 confers strong sensitization to
radiation-induced lymphoma. We conclude that Hipk2 is a
haploinsufﬁcient lymphoma suppressor gene.
Oncogene (2012) 31, 1176–1180; doi:10.1038/onc.2011.306;
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Introduction
The p53 tumor suppressor gene, one of most commonly
mutated genes in a wide spectrum of human and animal
tumors, controls cellular responses to DNA damage and
forms a critical link to downstream effectors of growth
arrest or cell death. We have previously described
a genetic screen for modiﬁers of p53-dependent or
-independent pathways leading to tumorigenesis in the
mouse (Cai et al., 2002; Mao et al., 2004, 2007). This
approach identiﬁed loci on chromosomes 3, 16 and 18,
which undergo genetic alterations, speciﬁcally in tumors
from mice carrying at least one functional p53 allele,
and are therefore likely to contain genes that mediate
p53 signaling during tumor development. Additional
loci on chromosomes 6, 12 and 19 showed genomic
changes that were completely independent of the
presence of p53. Detailed sublocalization of the com-
monest region of genomic alterations on chromosome 6
has enabled us to ﬁnd a locus, which contains only one
gene, the homeodomain interacting protein kinase 2
(Hipk2) gene.
Hipk2 is a recently identiﬁed serine/threonine nuclear
kinase that is highly conserved in mammalian organisms.
Hipk2 acts as a multi-functional transcriptional regulator
and corepressor that regulate cell growth, apoptosis,
proliferation and development. HIPK2 has been found to
be activated by a variety of DNA damaging agents,
including ultraviolet light, ionizing radiation and geno-
toxic chemotherapeutic drugs (D’Orazi et al., 2002;
Hofmann et al., 2002; Di Stefano et al., 2004; Dauth
et al., 2007). In response to DNA damage, HIPK2
activates human p53 by promoting site-speciﬁc phosphor-
ylation at Ser46 and subsequently activates apoptotic p53
target genes including PUMA, Noxa, DR5, PIG3,
p53AIP1 and Bax (D’Orazi et al., 2002; Hofmann et al.,
2002; Di Stefano et al., 2004; Pistritto et al., 2007). In
addition, HIPK2 has also been shown to interact with
and promote the degradation of CtBP in response to
ultraviolet-induced DNA damage, and can induce p53
independent apoptosis (Zhang et al., 2003). HIPK2 has
also been shown to induce phosphorylation and degrada-
tion of c-Myb through the Wnt signaling pathway in the
control of cell proliferation (Kanei-Ishii et al., 2004) and
to interact with several proteins containing the high
mobility group I domain, a highly conserved domain in
transcription factors of the lymphoid enhancer-binding
factor 1/T cell factor (LEF1-TCF) family (Pierantoni
et al., 2001, 2007). Our previous study showed that
germline deﬁciency of Hipk2 increased susceptibility to
two-stage chemically induced skin tumor development
(Wei et al., 2007), suggesting that Hipk2 may act as a
tumor suppressor gene. Herein, we demonstrate loss of
heterozygosity (LOH) of Hipk2 in radiation-induced
tumors from both p53þ/  and p53 /  mice and show
that Hipk2 deﬁciency in mice promotes g-radiation-
induced tumor development.
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Sublocalization of LOH regions on chromosome 6
A substantial proportion of lymphomas induced in
p53þ/  and p53 /  mice by g-radiation treatment
show LOH on chromosome 6 (Mao et al., 2004).
Although most of the tumors showed large-scale losses
involving the whole chromosome, several showed
discrete patterns of loss that implicated at least three
separate regions of deletion (Figure 1a). The smallest
interval identiﬁed from our initial screen was a 0.2-Mb
region between D6Mit91 and D6Mit222. This interval
encodes only the Hipk2 gene, a multi-functional
transcriptional cofactor that regulates cell growth and
proliferation. In a search for point mutations in the
Hipk2 coding region, the complete coding sequence was
determined from 20 tumors from p53þ/  mice and a
further 20 tumors from p53 /  mice. No point
mutations were found in any of the tumors. RNA was
available from all lymphomas that showed LOH at the
Hipk2 locus, and in all cases, the remaining Hipk2 allele
was present (Figure 1b), indicating that no gene
silencing had occurred. Further, we quantiﬁed the
expression of Hipk2 in radiation-induced thymic lym-
phoma by quantitative TaqMan analysis. Figure 1c
shows that 50% of tumors with LOH (7/14) had clearly
reduced Hipk2 mRNA levels in comparison with
normal thymus, or with tumors that retained both
parental alleles (retention of heterozygosity) of Hipk2.
We conclude that Hipk2 is subject to genetic changes
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Figure 1 LOH of Hipk2 in radiation-induced thymic lymphomas. (a) Detailed analysis of partial LOH patterns on chromosome 6
sublocalized three regions, denoted by the horizontal lines at the top of the ﬁgure. Physical mapping of markers and genes is based on
the Ensembl database. Tumors showing either complete loss of chromosome 6 or no change are not shown in the Figure. LOH region 1
is centered on Hipk2. (b) mRNA expression of Hipk2 in thymic lymphomas examined by RT–PCR, showing that all lymphomas
examined retained expression of the remaining allele of Hipk2 (c) Comparison of mRNA expression levels of Hipk2 in tumors with
LOH versus those with retention of heterozygosity using a quantitative TaqMan assay. The average expression level in tumors with
LOH (lanes 4–17) is reduced, compared with those without LOH (lanes 18–27), and with normal thymus (lanes 1–3).
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Oncogeneleading to reduced expression in a substantial propor-
tion of lymphomas from p53 heterozygous mice.
Hipk2 cooperates with p53 in g-radiation-induced
tumorigenesis
To investigate whether loss of Hipk2 accelerated
g-irradiation-induced tumorigenesis in vivo,3 7
Hipk2þ/  and 31 wild-type mice were exposed to a
single dose of 4-Gy g-irradiation at 5 weeks of age. At
the same time, 51 Hipk2þ/  and 34 wild-type mice
were left untreated and observed concurrently to
determine the spontaneous rate of tumor development.
Within 75 weeks, only one unirradiated Hipk2þ/ 
mouse, none of the unirradiated wild-type mice and two
irradiated wild-type mice developed tumors, in contrast
to more than 40% of irradiated Hipk2þ/  mice
(Figure 2a). We conclude that Hipk2 is a functional
tumor suppressor gene, loss of which increases suscept-
ibility to tumors induced by radiation exposure.
Importantly, loss of one allele of Hipk2 also accelerated
tumorigenesis in irradiated p53þ/  mice (P¼0.015
for tumorigenesis in 29 p53þ/  mice versus 36
Hipk2þ/ p53þ/  mice; Figure 2b), in agreement with
the observation of p53-independent deletions of this
chromosomal region in mouse lymphomas (Mao et al.,
2004).
Hipk2 is a haploinsufﬁcient tumor suppressor
Our observation of high frequency LOH, absence of
point mutations and any evidence of silencing of the
remaining allele suggested that Hipk2 might function as
a haploinsufﬁcient tumor suppressor gene. In agreement
with this interpretation, tumors from the Hipk2þ/ 
p53þ/  double heterozygous mice showed loss of the
remaining Hipk2 allele in only 1 of 20 tumors
investigated, whereas loss of the remaining p53 allele
was found in 18 of 20 tumors (Figure 3a). Expression of
Hipk2 was detected at the RNA level in tumors that had
retained the wild-type allele, indicating that no gene
silencing had taken place (Figure 3b). We conclude that
Hipk2 has many of the properties of a haploinsufﬁcient
tumor suppressor gene, in that loss of one copy confers
predisposition without requiring complete inactivation
of the remaining allele.
Discussion
In this report, we have shown that LOH of the mouse
Hipk2 gene occurs frequently in radiation-induced
thymic lymphomas. Most tumors retain and express
one copy of the wild-type allele, demonstrating that the
Hipk2 gene has a haploinsufﬁcient role in mouse
lymphoma development. Deletion analysis of lympho-
ma DNA samples allowed us to localize the smallest
common region of deletion to a 200-kb region contain-
ing only Hipk2, thus identifying this gene as the most
viable candidate tumor suppressor.
A functional role for Hipk2 in lymphomagenesis was
demonstrated using mice carrying germline mutations in
the Hipk2 gene. Hipk2 heterozygous mice are susceptible
to radiation-induced tumorigenesis, but tumors retained
and expressed the wild-type allele, in agreement with the
hypothesis that loss of a single gene copy is sufﬁcient to
impact tumor susceptibility. Our observations of a
haploinsufﬁcient effect of Hipk2 loss in lymphomagen-
esis suggests that chromosome changes resulting in copy
number changes on human chromosome 7q34, where
HIPK2 is located, may have a role in development of
human leukemias and solid tumors in which this
chromosome undergoes somatic alterations (Mitelman
et al., 2010). Others have reported rare HIPK2 muta-
tions in AML (Li et al., 2007), but there are also reports
of ampliﬁcation of HIPK2 in some cancers (Deshmukh
et al., 2008), suggesting a complex role that is context
dependent. This complexity is further underlined by
apparently contradictory results on the effects of Hipk2
on cell growth. Pierantoni et al. (2001) demonstrated
that Hipk2 can act as a suppressor of proliferation, but
nevertheless cells from Hipk2 knockout (KO) mice have
variously been reported to exhibit decreased (Trapasso
et al., 2009) or increased (Wei et al., 2007) cell growth
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Figure 2 Hipk2-deﬁcient mice are susceptible to radiation-induced
tumor development. (a) Spontaneous and radiation-induced
tumorigenesis in Hipk2þ/  and wild-type mice. 37 Hipk2þ/ 
and 31 wild-type mice were exposed to a single dose of a 4-Gy g-
irradiation at 5 weeks of age. At the same time, 51 Hipk2þ/  and
34 wild-type mice acted as unirradiated controls. (b) Radiation-
induced tumorigenesis in double heterozygous Hipk2þ/ p53þ/ 
(n¼36) and p53þ/  (n¼29) mice, showing the cooperative effects
of partial deﬁciency in both genes.
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Oncogenein vitro. The reasons or these discrepancies are
unclear, and may be related to the speciﬁc nature of
the KO alleles or the genetic background from which the
cells were derived. Our data demonstrate conclusively
that Hipk2 is a tumor suppressor gene in vivo; however,
the fact that tumors retain and express one wild-type
allele suggests that complete Hipk2 loss may in some
way be detrimental to tumor growth. The mechanistic
basis for the positive or negative effects of Hipk2 on
cell growth and tumor development remains to be
established.
Although HIPK2 has been implicated in regulating
p53-dependent cell growth and apoptosis (D’Orazi et al.,
2002; Hofmann et al., 2002), our studies on radiation-
induced tumor development in the Hipk2/p53 double
heterozygous mice show that the activities of these two
genes in lymphomagenesis are independent, as germline
deletion of one copy of both genes shows additive effects
on lymphoma susceptibility.
Independent effects of loss of p53 and of Hipk2 were
also evident during the somatic events involved in tumor
progression, as loss of one Hipk2 allele was also found in
tumors from p53 /  mice. Documented p53-indepen-
dent functions of HIPK2 include induction of apoptosis
upon DNA damage, through proteasomal degradation
of CtBP (Zhang et al., 2003), but whether this
mechanism is linked to the tumor suppressor role of
Hipk2 in lymphoma susceptibility and progression
remains to be determined.
Materials and methods
Mice and tumor induction
p53 and Hipk2 single or double heterozygous KO mice were
generated by crossing Hipk2þ/  heterozygous KO (Wei et al.
2007) with p53þ/  heterozygous KO mice (C57BL/6J),
purchased from The Jackson Laboratories (Bar Harbor, ME,
USA). Mice at 5 weeks of age of both sexes were exposed to a
single dose of 4-Gy whole body g-irradiation and monitored daily
until moribund, then killed and autopsied. Mice were bred and
treated under University of California at San Francisco (UCSF)
Laboratory Animal Resource Center (LARC) regulations.
Preparation of DNA
Thymic lymphomas and normal tissues were minced and placed
in a microfuge tube containing 0.5ml lysis buffer (100mM Tris–
HCl, pH 8.5; 5mM ethylene diamine tetraacetic acid, 0.2%
sodium dodecyl sulfate, 200mM NaCl). Proteinase K was added
at a ﬁnal concentration of 100mg/ml and incubated at 551C
overnight. The lysate was extracted twice with an equal volume
of phenol:chloroform:isoamyl alcohol (25:24:1, v/v) (GibcoBRL,
Carlsbad, CA, USA). DNA in the lysate was precipitated by
addition of an equal volume of isopropanol. The DNA
precipitates were solubilized in TE buffer (10mM Tris–HCl,
pH 8.0 and 1mM ethylene diamine tetraacetic acid).
Sublocalizing LOH on chromosome 6 by PCR of microsatellite
markers
LOH was determined by PCR of microsatellite markers, with
normal and tumor DNA from the same mice. Map position
was based on the Ensembl (http://uswest.ensembl.org/Mus_
musculus). The primers for microsatellite marker within the
Hipk2 gene are: F: AGCTTAGATGGTCTGTGGAA; R: GC
AGGTCTCTACTAGCATGG.
PCR primer pairs for markers were purchased from Qiagen
Operon (www.operon.com). PCR reactions were set up in a
total volume of 20ml, containing 2mlo f1 0   PCR buffer
(Bioline, Tauton, MA, USA), 1.6ml of 2.5mM dNTPs
(Pharmacia Biosystem Ltd, Piscataway, NJ, USA), 1ml
(6.6mM) of each primer, 0.6mlo f5 0 m M MgCl2 (Bioline),
11.7mld H 2O, 0.1ml Taq polymerase (Bioline) and 2ml (40ng/
ml) tumor or normal tissue DNA. Ampliﬁcations were initially
denatured at 941C for 3min, followed by 35 cycles at 941C for
30s, 551Co r5 21C for 30s and 721C for 30s, and then a ﬁnal
incubation at 721C for 5min. The PCR products were
then mixed with loading buffer and electrophoresed in 4%
(3% NuSieve/1% agarose) agarose gel with 0.5mg/ml
ethidium-bromide, photographed and saved in image ﬁle for
analysis of density of bands.
Mutational analysis of the Hipk2 coding region
Total RNA was extracted from tumor tissue samples with the
TRIzol Reagent (Invitrogen Life Technologies, Carlsbad, CA,
USA). Reverse transcription PCR reactions were performed
using Thermoscript RT–PCR system (GibcoBRL) according
to the manufacturer’s instructions. Mutation analysis of the
Hipk2 gene was performed by PCR ampliﬁcation of cDNA
from thymic lymphomas by using the following primers:
Hipk2
p53
KO
WT
KO
WT
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Thymic lymphomas from p53+/-Hipk2+/- mice
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Figure 3 Hipk2 is a haploinsufﬁcient tumor suppressor gene. (a) LOH analysis of thymic lymphomas from Hipk2þ/ p53þ/  mice
on chromosome 6 and 11. PCR analysis was carried out on 20 matched normal—tumor DNA samples to investigate loss of the
wild-type alleles of Hipk2 (top panel) and p53 (bottom panel). Only one tumor (number 6) showed loss of the wild-type Hipk2 allele,
but 18/20 showed loss of the wild-type p53 allele. (b) Expression analysis of Hipk2 in thymic lymphomas from Hipk2þ/ p53þ/ 
mice by RT–PCR analysis. Only tumor number6 that had lost the wild-type Hipk2 allele showed complete loss of Hipk2 expression.
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OncogeneF1: TCAAGTGCCTTCTGTAGTGTGAA; R1: CATAAA
GGTTCTGCTCCAACATC; F2: GAGTGCTTCCAGCAC
AAGAAC; R2: TAACAGGTCAATGAACTCCCG; F3: GG
ACAAAGACAACTAGGTTTTTCAA; R3: TGGTAGTTT
AGTATGGAGACTTCGG; F4: CCAATCCCGAAGTCTC
CATA; R4: TGGTTGTTGCCTCATCACAT; F5: GCATG
CAGCTGTGATTCCT; R5: GTGTCCAAGGTGTTGGT
GC; F6: CAAGCGTGTCAAGGAGAACA; R6: AGCTCCC
TGAAGAGTGTCCA; F7: CAGTCACCATTCGTCCTC
CT; R7: GGTCTCTTCTCCGCTCTCAA.
PCR products were puriﬁed by gel electrophoresis and
sequenced by Quintarabio (www.quintarabio.com).
Detection of Hipk2 mRNA expression using Taqman assay
Total RNAs from all tumors and three normal thymuses were
used to assess Hipk2 mRNA expression by TaqMan Assays-
on-Demand (Mm00439329_m1), purchased from Applied
Biosystems (Carlsbad, CA, USA). Hipk2 expression was
measured using the ABI PRISM 7700 sequence detection
system (Applied Biosystems). PCR reactions were performed
in triplicate for each sample and experiments were repeated a
minimum of three times. Ct values were normalized against b-
actin RNA (DCt¼Ct of Hipk2 Ct of b-actin). The relative
Hipk2 expression was calculated by 2^( DDCt), where
DDCt¼(DCt of sample) (average DCt of three normal
thymuses).
Statistical analysis
The Mann–Whitney U-test was used to compare the expres-
sion levels of Hipk2 between tumors with LOH and retention
of heterozygosity. The Kaplan–Meier method was used to
compare the survival time post-radiation between different
groups of genotypes of mice using the SPSS statistical package
(SPSS, Armonk, NY, USA).
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